Ceritinib is an anaplastic
lymphoma kinase (ALK) inhibitor used
for the treatment of ALK-positive metastatic non-small cell lung cancer
(NSCLC). This BCS class IV drug is developed by Novartis and traded
under the name Zykadia. To date two forms [Form A (marketed form) and B] of ceritinib are disclosed
in international patent application US 2013/0274279 A1. However, the
crystal structure and insight into any solid form of this compound
are not available in the literature. In order to achieve better physicochemical
properties compared to known solid forms of this compound, novel polymorph
identification is chosen as one of the challenging paths to address
the issue. In our comprehensive polymorph screening, including in
silico and experimental investigations, we discovered three novel
solid forms of ceritinib. Out of these three solid forms, two are
neat (Form 1 and Form 3) and the remaining one is a hydrate (Form
2). All synthesized forms are further characterized by powder X-ray
diffraction, differential scanning calorimetry, and Fourier transform
infrared spectroscopy. It is interesting to note that the discovery
of this hydrate is in sync with the prediction done using COSMO-RS
theory (COSMOthermX software). The current article includes the first
single crystal structure of ceritinib Form 1. All forms (Form 1, 2,
and 3) of ceritinib are subjected to physicochemical property evaluation
like solubility in buffers with a pH range of 1–7, dissolution,
and stability. In aqueous solutions and pH 4.5 (acetate buffer), the
solubility of Form 2 and 3 is high compared to Form 1, whereas in
0.1 N HCl and 0.01 N HCl Form 1 has a higher solubility compared to
Forms 2 and 3. A six-month stability study indicates that all forms
(Forms 1, 2, and 3) are stable in ICH stability conditions like accelerated
(40 °C ± 2 °C, 75% RH ± 5% RH), long-term (25
°C ± 2 °C, 60% RH ± 5% RH), and low temperature
(2–8 °C) conditions. A thorough polymorph screening protocol,
including in silico prediction, single crystal structure, and physicochemical
properties of different forms and structure property correlations
for ceritinib are enlightened in the current paper.